Caroline Loew - Mural Oncology CEO President
| MURA Stock | 3.44 0.20 5.49% |
CEO
Caroline Loew is CEO President of Mural Oncology plc
| Age | 53 |
| Address | 10 Earlsfort Terrace, Dublin, Ireland, D02 T380 |
| Phone | 353 1 905 8020 |
| Web | https://www.muraloncology.com |
Latest Insider Transactions
Caroline Loew Latest Insider Activity
Tracking and analyzing the buying and selling activities of Caroline Loew against Mural Oncology stock is an integral part of due diligence when investing in Mural Oncology. Caroline Loew insider activity provides valuable insight into whether Mural Oncology is net buyers or sellers over its current business cycle. Note, Mural Oncology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mural Oncology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Caroline Loew over three months ago Disposition of 12531 shares by Caroline Loew of Mural Oncology at 2.91 subject to Rule 16b-3 |
Mural Oncology Management Efficiency
The company has return on total asset (ROA) of (0.8105) % which means that it has lost $0.8105 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7834) %, meaning that it created substantial loss on money invested by shareholders. Mural Oncology's management efficiency ratios could be used to measure how well Mural Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of December 17, 2024, Return On Tangible Assets is expected to decline to -0.72. In addition to that, Return On Capital Employed is expected to decline to -0.75. At present, Mural Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 291.2 M, whereas Non Current Assets Total are forecasted to decline to about 22.5 M.Similar Executives
| Found 1 records | CEO Age | ||
| Dinesh Patel | Protagonist Therapeutics | 67 | |
Management Performance
| Return On Equity | -1.78 | ||||
| Return On Asset | -0.81 |
Mural Oncology plc Leadership Team
Elected by the shareholders, the Mural Oncology's board of directors comprises two types of representatives: Mural Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mural. The board's role is to monitor Mural Oncology's management team and ensure that shareholders' interests are well served. Mural Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mural Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam BA, Principal CFO | ||
| Caroline Loew, CEO President | ||
| Justin Levine, Head Resources | ||
| Vicki MD, Chief Officer | ||
| Maiken KesonBrookes, Chief Officer |
Mural Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mural Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.78 | ||||
| Return On Asset | -0.81 | ||||
| Current Valuation | (103.86 M) | ||||
| Shares Outstanding | 17.06 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 69.43 % | ||||
| Number Of Shares Shorted | 476.66 K | ||||
| Price To Book | 0.36 X | ||||
| EBITDA | (192.72 M) | ||||
| Net Income | (207.45 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mural Oncology plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.03) | Return On Assets (0.81) | Return On Equity (1.78) |
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.